Philippe Pourquier

List of Publications by Year
in descending order

66 papers	3,919 citations	159358 30 h-index	118652 62 g-index
75 all docs	75 docs citations	75 times ranked	4228 citing authors

#	Article	IF	Citations
1	Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry. International Journal of Molecular Sciences, 2022, 23, 5701.	1.8	0
2	Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells. Pharmaceuticals, 2021, 14, 624.	1.7	6
3	PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1. Cancers, 2021, 13, 3635.	1.7	10
4	The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor. Cells, 2020, 9, 1641.	1.8	13
5	High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor. Cells, 2020, 9, 1469.	1.8	11
6	Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins. Nucleic Acids Research, 2019, 47, 5511-5521.	6.5	15
7	Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. Cancer Medicine, 2018, 7, 1575-1577.	1.3	6
8	Single helically folded aromatic oligoamides that mimic the charge surface of double-stranded B-DNA. Nature Chemistry, 2018, 10, 511-518.	6.6	56
9	LINE-1 as a therapeutic target for castration-resistant prostate cancer. Frontiers in Bioscience - Landmark, 2018, 23, 1292-1309.	3.0	11
10	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer, 2018, 18, 194.	1.1	18
11	Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells. Redox Biology, 2018, 18, 33-42.	3.9	19
12	Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 653-659.	1.1	13
13	Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. Journal of Negative Results in BioMedicine, 2015, 14, 18.	1.4	2
14	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. British Journal of Cancer, 2015, 112, 688-692.	2.9	18
15	Polymorphisms inSLCO1B3andNR1I2as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics, 2015, 16, 1439-1450.	0.6	14
16	Targeting the genetic alterations of the PI3Kâ€“AKTâ€“mTOR pathway: Its potential use in the treatment of bladder cancers. , 2015, 145, 1-18.		75
17	Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer.. Journal of Clinical Oncology, 2015, 33, 304-304.	0.8	2
18	From old alkylating agents to new minor groove binders. Critical Reviews in Oncology/Hematology, 2014, 89, 43-61.	2.0	96

#	Article	IF	Citations
19	Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status. Onkologie, 2013, 36, 670-673.	1.1	7
20	The Polyphenolic Ellagitannin Vescalagin Acts As a Preferential Catalytic Inhibitor of the Î± Isoform of Human DNA Topoisomerase II. Molecular Pharmacology, 2012, 82, 134-141.	1.0	31
21	Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis, 2012, 33, 962-968.	1.3	13
22	Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin. Molecular Pharmacology, 2012, 82, 1205-1216.	1.0	4
23	DNA Topoisomerase I and Illegitimate Recombination. Cancer Drug Discovery and Development, 2012, , 119-143.	0.2	0
24	Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. European Urology Supplements, 2011, 10, e20-e25.	0.1	4
25	New Topoisomerase I mutations are associated with resistance to camptothecin. Molecular Cancer, 2011, 10, 64.	7.9	56
26	ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer, 2011, 117, 3445-3456.	2.0	57
27	Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma. Cancer Research, 2011, 71, 1041-1049.	0.4	72
28	The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells. PLoS ONE, 2009, 4, e5493.	1.1	22
29	Protein arginine (N)â€methyl transferase 7 (PRMT7) as a potential target for the sensitization of tumor cells to camptothecins. FEBS Letters, 2008, 582, 1483-1489.	1.3	49
30	Inhibition of Topoisomerase I Cleavage Activity by Thiol-reactive Compounds. Journal of Biological Chemistry, 2007, 282, 14403-14412.	1.6	22
31	Genetic polymorphisms of the XPG and XPD nucleotide excision repair genes in sarcoma patients. International Journal of Cancer, 2006, 119, 1732-1735.	2.3	18
32	The DNA polymerase Â is required for the repair of non-compatible DNA double strand breaks by NHEJ in mammalian cells. Nucleic Acids Research, 2006, 34, 2998-3007.	6.5	90
33	The Chemistry of Wine PolyphenolicC-Glycosidic Ellagitannins Targeting Human Topoisomerase II. Chemistry - A European Journal, 2005, 11, 6503-6513.	1.7	130
34	Predicting drug response and toxicity based on gene polymorphisms. Critical Reviews in Oncology/Hematology, 2005, 54, 171-196.	2.0	96
35	Apoptotic Topoisomerase I-DNA Complexes Induced by Staurosporine-mediated Oxygen Radicals. Journal of Biological Chemistry, 2004, 279, 50499-50504.	1.6	62
36	Predicting drug response based on gene expression. Critical Reviews in Oncology/Hematology, 2004, 51, 205-227.	2.0	15

#	Article	IF	Citations
37	Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations. Journal of Molecular Biology, 2004, 339, 773-784.	2.0	129
38	Structural Basis for Topoisomerase I Inhibition by Nucleoside Analogs. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 653-658.	0.4	20
39	Elongation of oligonucleotide primers forming a triple helix on double-stranded DNA templates by purified DNA polymerases. Biochemical and Biophysical Research Communications, 2003, 311, 380-385.	1.0	8
40	Human Apurinic/Apyrimidinic Endonuclease (Ape1) and Its N-terminal Truncated Form (AN34) Are Involved in DNA Fragmentation during Apoptosis. Journal of Biological Chemistry, 2003, 278, 37768-37776.	1.6	48
41	De nouveaux rÃ1es pour lâ€™ADN topo-isomÃ©rase I. Medecine/Sciences, 2002, 18, 975-981.	0.0	1
42	Interaction of Human Nuclear Topoisomerase I with Guanosine Quartet-forming and Guanosine-rich Single-stranded DNA and RNA Oligonucleotides. Journal of Biological Chemistry, 2002, 277, 8906-8911.	1.6	51
43	Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clinical Cancer Research, 2002, 8, 2499-504.	3.2	82
44	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Medicine, 2001, 7, 961-966.	15.2	339
45	Topoisomerase I-mediated DNA damage. Advances in Cancer Research, 2001, 80, 189-216.	1.9	182
46	Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2040-2045.	3.3	65
47	Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1885-1890.	3.3	100
48	Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate. Journal of Biological Chemistry, 2000, 275, 15246-15253.	1.6	35
49	Topoisomerase Poisoning Activity of Novel Disaccharide Anthracyclines. Molecular Pharmacology, 1999, 56, 77-84.	1.0	58
50	DNA Protein Cross-Links Produced by NSC 652287, a Novel Thiophene Derivative Active Against Human Renal Cancer Cells. Molecular Pharmacology, 1999, 56, 478-484.	1.0	63
51	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Research, 1999, 27, 1919-1925.	6.5	34
52	Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages. Journal of Biological Chemistry, 1999, 274, 8516-8523.	1.6	168
53	Topoisomerase I and II Activity Assays. , 1999, 28, 95-110.		2
54	Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resistance Updates, 1999, 2, 307-318.	6.5	158

#	Article	IF	Citations
55	Gadd45, a p53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin. Molecular and Cellular Biology, 1999, 19, 1673-1685.	1.1	251
56	Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 83-106.	2.4	476
57	Doxorubicin-Induced Alterations of c-myc and c-jun Gene Expression in Rat Glioblastoma Cells: Role of c-jun in Drug Resistance and Cell Death. Biochemical Pharmacology, 1998, 55, 1963-1971.	2.0	17
58	Induction of Topoisomerase I Cleavage Complexes by the Vinyl Chloride Adduct 1,N 6-Ethenoadenine. Journal of Biological Chemistry, 1998, 273, 27245-27249.	1.6	40
59	Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. Anti-Cancer Drugs, 1998, 9, 245-254.	0.7	11
60	Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I. Journal of Biological Chemistry, 1997, 272, 7792-7796.	1.6	164
61	Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps. Journal of Biological Chemistry, 1997, 272, 26441-26447.	1.6	153
62	Differential Stabilization of Topoisomerase-II-DNA Cleavable Complexes by Doxorubicin and Etoposide in Doxorubicin-Resistant Rat Glioblastoma Cells. FEBS Journal, 1997, 245, 307-315.	0.2	16
63	Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture. Anti-Cancer Drugs, 1996, 7, 738-744.	0.7	21
64	Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-Cancer Drugs, 1995, 6, 135-146.	0.7	11
65	Differential over-expression ofmdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine. International Journal of Cancer, 1993, 55, 115-121.	2.3	17
66	Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. FEBS Journal, 1993, 211, 141-146.	0.2	47